Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC
New drug combo extends life for some prostate cancer patients
This retrospective cohort study of 5 patients with HRR-mutated metastatic castration-resistant prostate cancer evaluated niraparib plus abir…
Some men with advanced prostate cancer are living longer with a powerful new drug combo, even when they’re older or too weak for harsh treat…
Low-dose IVIG shows similar efficacy to standard-dose IVIG in adults with AChR-positive generalized myasthenia gravis.
Low-Dose IVIG Works as Well as High-Dose for MG
This prospective single-center cohort study evaluated low-dose versus standard-dose intravenous immunoglobulin (IVIG) in 34 adults with AChR…
A much smaller dose of IVIG may relieve severe muscle weakness in myasthenia gravis just as well as the standard high dose—cutting treatment…
Case Report Describes Treatment of Severe Mosquito Bite Allergy and EBV-Associated NK-Cell Lymphoproliferative Disorder
Why a 70-Year-Old Man’s Mosquito Bites Turned Deadly
This case report details the clinical management of a 70-year-old male with severe mosquito bite allergy and EBV-associated NK-cell lymphopr…
A single mosquito bite can sometimes signal a hidden immune problem, especially in older adults.
Combined Therapy for Febrile Ulceronecrotic Mucha-Habermann Disease in Young Children: Case Report and Review
Doctors Heal Rare Skin Condition in Toddler Using Drug Combo
This publication is a case report and literature review focusing on Febrile ulceronecrotic Mucha-Habermann disease in preschool-aged childre…
A rare and painful skin disease in young children may now have a clearer path to recovery.
Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients.
New Drug Combo Helps Most Patients With Hard-to-Treat Lymphoma
This phase 1b multicenter clinical trial evaluated mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, and pred…
A new drug combo wrapped in fat bubbles helped 89% of patients with hard-to-treat lymphoma shrink tumors without causing deaths.
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation.
Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Case report: Low-intensity chemotherapy achieves remission in PMF transformed to MPAL
Single case report describes treatment for rare leukemia transformation in elderly patient
A case report describes a 75-year-old female with JAK2V617F-positive primary myelofibrosis that transformed to mixed phenotype acute leukemi…
A 75-year-old woman with rare leukemia transformation from blood disorder achieved remission after two cycles of low-intensity chemotherapy.
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case
Rituximab treatment reduced kidney protein loss in one Sjögren's syndrome patient
A case report describes a 48-year-old female with primary Sjögren's syndrome and nephrotic-range proteinuria treated with prednisone and rit…
A 48-year-old woman with Sjögren's syndrome saw her kidney protein loss drop from 8.5 to 2.2 grams after receiving rituximab treatment.
R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
Can adding a drug cocktail to radiation help keep early lymphoma from returning?
In a multicenter RCT with 150 patients with early-stage follicular lymphoma and 11.3-year median follow-up, involved-field radiotherapy plus…
Adding R-CVP drugs to radiation therapy helps early-stage lymphoma patients stay cancer-free longer, with mostly temporary side effects and …
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Can a new drug combination help people with aggressive multiple myeloma? Early results show promise.
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…